US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,490.89

+14.160.96%

Number of Gainers:2

Number of Losers:9

Number of Flat:- -

PE:- -

High:1,516.24

Open:1,476.55

Low:1,468.84

Close:1,476.73

Loading ...

GeoVax Labs Inc. Conducted Annual Stockholders Meeting

Aethlon Medical Approves Reverse Stock Split Plan

Aethlon Medical Inc. Announces 1-for-8 Reverse Stock Split Effective June 9, 2025

Emergent BioSolutions teams up with Victoria’s Voice Foundation

A New Shot Prevents HIV and Breathes New Life Into a Stagnant Biotech -- Heard on the Street -- WSJ

Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value

Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc

BRIEF-Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial Of Mr-142 In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Viatris Inc. Announces Breakthrough Phase 3 Trial Results for MR-142, Pioneering Treatment for Night Driving Impairment in Keratorefractive Patients

Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial of Mr-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

THOMSON REUTERS

Viatris Inc - Results Show Functional Benefit in Treating Night Driving Impairment

THOMSON REUTERS

Viatris Inc - Mr-142 Achieved Primary Endpoint of ≥15-Letter Gain in Mlcva

THOMSON REUTERS

Viatris Inc - No Evidence of Tachyphylaxis Observed Over 6-Week Period

THOMSON REUTERS

Gilead Sciences (GILD) Gets a Hold from Truist Financial

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)

Gilead’s Kite announces real-world safety, effectiveness of Yescarta

Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer

Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1490.8878,"timestamp":1749153599999,"preClose":1476.7268,"halted":0,"volume":29203882,"delay":0,"changeRate":0.009589,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":14.161011,"latestTime":"06-05 16:00:00 EDT","open":1476.5529,"high":1516.2367,"low":1468.8363,"amount":1460161646.538654,"amplitude":0.032098,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749196800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.900204,"peRate":61.492422,"turnoverRate":0.010874,"increases":2,"decrements":9,"flats":0,"marketCap":167855392848.5,"floatMarketCap":167203287484.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1516.2367,"amplitude":0.032098,"preClose":1476.7268,"low":1468.8363,"pbRate":"3.900204","latestPrice":1490.8878,"volume":29203882,"delay":0,"open":1476.5529,"prevYearClose":1284.7982,"prevWeekClose":1489.9341,"prevMonthClose":1489.9341,"prevQuarterClose":1502.9401,"fiveDayClose":1500.8724,"twentyDayClose":1365.2736,"sixtyDayClose":1535.3859,"secType":"PLATE","market":"US","turnoverRate":0.010874,"peRate":61.492422,"marketCap":167855392848.5,"floatMarketCap":167203287484.875,"timestamp":1749153599999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":2,"down":9,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541500668","title":"GeoVax Labs Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541500668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541500668?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:41","pubTimestamp":1749156061,"startTime":"0","endTime":"0","summary":"GeoVax Labs Inc. held its annual meeting of stockholders on June 5, 2025. During the meeting, stockholders voted on several proposals. The slate of directors consisting of seven members was elected. The GeoVax Labs, Inc. 2025 Stock Incentive Plan was approved. The proposal to issue up to 3,435,115 shares of common stock upon exercise of a warrant was approved. Additionally, the ratification of Wipfli LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8ndKNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","GOVX"],"gpt_icon":0},{"id":"2541073333","title":"Aethlon Medical Approves Reverse Stock Split Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2541073333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541073333?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:58","pubTimestamp":1749128303,"startTime":"0","endTime":"0","summary":"Aethlon Medical ( ($AEMD) ) has provided an update. Aethlon Medical, Inc. held a Special Meeting of Stockholders on May 13, 2025, where a reverse s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-approves-reverse-stock-split-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aethlon-medical-approves-reverse-stock-split-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","AEMD","BK4082","BK4583"],"gpt_icon":0},{"id":"2541858078","title":"Aethlon Medical Inc. Announces 1-for-8 Reverse Stock Split Effective June 9, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2541858078","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541858078?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:31","pubTimestamp":1749126688,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-8, effective at 5:00 p.m. Eastern Time on June 6, 2025. Trading will commence on a split-adjusted basis on June 9, 2025, on The Nasdaq Capital Market. The company's new CUSIP number post-split is 00808Y 505. This move will proportionately affect all shareholders, adjusting the per share exercise price and number of shares tied to stock options, restricted stock units, and warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL2X01Sb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","AEMD","BK4082","BK4583"],"gpt_icon":0},{"id":"2541221710","title":"Emergent BioSolutions teams up with Victoria’s Voice Foundation","url":"https://stock-news.laohu8.com/highlight/detail?id=2541221710","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541221710?lang=en_us&edition=fundamental","pubTime":"2025-06-05 19:10","pubTimestamp":1749121837,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions (EBS) is teaming up with Victoria’s Voice Foundation to rally Americans to help save lives from the opioid epidemic on Nation...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emergent-biosolutions-teams-up-with-victorias-voice-foundation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emergent-biosolutions-teams-up-with-victorias-voice-foundation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4095","EBS","BK4583","BK4139","VCCTF"],"gpt_icon":0},{"id":"2541025380","title":"A New Shot Prevents HIV and Breathes New Life Into a Stagnant Biotech -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2541025380","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541025380?lang=en_us&edition=fundamental","pubTime":"2025-06-05 17:30","pubTimestamp":1749115800,"startTime":"0","endTime":"0","summary":"Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to prevent HIV -- a milestone in the decadeslong fight against a once-devastating disease.For Gilead Sciences, the dominant player in HIV treatment, the breakthrough is doing what years of splashy but underwhelming acquisitions failed to achieve: It has Wall Street paying attention again. Since reporting last June that just two annual shots of lenacapavir prevented all HIV infections in a study of women and girls, shares have surged 73%.Still, hurdles remain. Stigma continues to hinder PrEP uptake, particularly outside the core demographic of white men who have sex with men. Black Americans account for 39% of new HIV diagnoses but just 14% of PrEP users. Expanding access to underserved populations will require continued insurance coverage. While most current users are covered by commercial insurance, Medicaid will be key to reaching lower-income groups -- making rece","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","IE00B3T34201.USD","BK4578","LU1674673691.USD","IE00B19Z3581.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","LU0889565916.HKD","LU0823416689.USD","BK4566","LU2089984988.USD","LU0109394709.USD","LU1839511570.USD","BK4532","BK4588","BK4568","LU1778281490.HKD","LU0320765992.SGD","LU1571399168.USD","LU1674673428.USD","IE00B19Z3B42.SGD","LU1066051498.USD","LU1066053197.SGD","IE00BKVL7J92.USD","GILD","IE00BSNM7G36.USD","LU2087621335.USD","BK4139","LU1585245621.USD","BK4550","LU0058720904.USD","LU1430594728.SGD","BK4583","IE0002270589.USD","LU2468319806.SGD","LU0234570918.USD","BK4585"],"gpt_icon":0},{"id":"2541103670","title":"Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2541103670","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541103670?lang=en_us&edition=fundamental","pubTime":"2025-06-05 12:27","pubTimestamp":1749097674,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Daina Graybosch maintained a Buy rating on Gilead Sciences (GILD – Research Report) on June 2 and set a price target of $1...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/gilead-sciences-oncology-advancements-trodelvys-potential-to-boost-stock-value-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/gilead-sciences-oncology-advancements-trodelvys-potential-to-boost-stock-value-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","LU0823416689.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU1674673428.USD","LU2089984988.USD","LU1066051498.USD","LU1839511570.USD","BK4139","LU1778281490.HKD","BK4578","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0320765992.SGD","LU2087621335.USD","LU0109394709.USD","LU1066053197.SGD","IE00BKVL7J92.USD","LU0058720904.USD","BK4585","IE00BZ1G4Q59.USD","BK4568","BK4550","LU0234570918.USD","LU1430594728.SGD","LU0889565916.HKD","LU1674673691.USD","IE00BSNM7G36.USD","BK4566","IE0002270589.USD","LU1585245621.USD","BK4532","BK4583","LU0289739699.SGD","BK4588","IE00B19Z3581.USD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2540871443","title":"Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540871443","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540871443?lang=en_us&edition=fundamental","pubTime":"2025-06-03 08:56","pubTimestamp":1748912188,"startTime":"0","endTime":"0","summary":"Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL1PrYrW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","BK4588","LU1839511570.USD","LU2087621335.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU1430594728.SGD","LU0109394709.USD","LU0823416689.USD","BK4583","BK4568","IE00BSNM7G36.USD","LU0234570918.USD","LU1066051498.USD","LU0889565916.HKD","LU1066053197.SGD","LU1585245621.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4566","BK4578","LU0320765992.SGD","BK4585","LU2089984988.USD","GILD","LU2468319806.SGD","BK4139","IE00B3T34201.USD","LU1674673691.USD","BK4532","BK4550","IE00BKVL7J92.USD","IE0002270589.USD","LU1571399168.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2540985687","title":"BRIEF-Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial Of Mr-142 In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2540985687","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540985687?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:19","pubTimestamp":1748866787,"startTime":"0","endTime":"0","summary":"BRIEF-Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial Of Mr-142 In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsJune 2 (Reuters) - Via","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3QBSST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","LU2087621335.USD","BK4583","LU1839511570.USD","VTRS","BK4588"],"gpt_icon":0},{"id":"2540607517","title":"Viatris Inc. Announces Breakthrough Phase 3 Trial Results for MR-142, Pioneering Treatment for Night Driving Impairment in Keratorefractive Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2540607517","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540607517?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:01","pubTimestamp":1748865708,"startTime":"0","endTime":"0","summary":"Viatris Inc. Announces Breakthrough Phase 3 Trial Results for MR-142, Pioneering Treatment for Night Driving Impairment in Keratorefractive Patients. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire  on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL2RwLGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","LU1839511570.USD","VTRS","BK4583","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2540760478","title":"Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial of Mr-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760478?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865611,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3QBSST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","LU1839511570.USD","BK4588","BK4585","LU2087621335.USD","BK4007","VTRS"],"gpt_icon":0},{"id":"2540760477","title":"Viatris Inc - Results Show Functional Benefit in Treating Night Driving Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760477?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865611,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3QBSST:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2087621335.USD","BK4583","BK4585","LU1839511570.USD","BK4007","BK4588","VTRS"],"gpt_icon":0},{"id":"2540676040","title":"Viatris Inc - Mr-142 Achieved Primary Endpoint of ≥15-Letter Gain in Mlcva","url":"https://stock-news.laohu8.com/highlight/detail?id=2540676040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540676040?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865611,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3QBSST:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4588","BK4585","VTRS","LU1839511570.USD","BK4007","LU2087621335.USD"],"gpt_icon":0},{"id":"2540604737","title":"Viatris Inc - No Evidence of Tachyphylaxis Observed Over 6-Week Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2540604737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540604737?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865611,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3QBSST:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4585","BK4588","VTRS","BK4007","LU2087621335.USD","LU1839511570.USD"],"gpt_icon":0},{"id":"2540976719","title":"Gilead Sciences (GILD) Gets a Hold from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540976719","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540976719?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:17","pubTimestamp":1748863029,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-hold-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-hold-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IE00BKVL7J92.USD","LU1066053197.SGD","BK4532","LU0823416689.USD","GILD","BK4568","LU1778281490.HKD","LU1674673428.USD","BK4588","LU2468319806.SGD","BK4566","IE00B7SZLL34.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4583","LU2089984988.USD","BK4139","BK4578","LU1674673691.USD","LU1585245621.USD","LU0058720904.USD","LU0234570918.USD","LU0109394709.USD","IE00B19Z3581.USD","LU1430594728.SGD","IE00B3T34201.USD","BK4585","LU1066051498.USD","LU1571399168.USD","IE0002270589.USD","LU2087621335.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU0289739699.SGD","IE00BSNM7G36.USD","BK4550"],"gpt_icon":0},{"id":"2540775191","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540775191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540775191?lang=en_us&edition=fundamental","pubTime":"2025-06-02 10:50","pubTimestamp":1748832607,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Gilead Science...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-and-gilead-sciences-gild-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-and-gilead-sciences-gild-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0965508806.USD","LU1934455277.USD","LU0234572021.USD","LU0417517546.SGD","BK4532","IE00B2B36J28.USD","LU1551013425.SGD","LU0912757837.SGD","IE00BGHQF631.EUR","LU0256863811.USD","LU2237443382.USD","LU0128525929.USD","ABBV","LU1037948541.HKD","HCSG","LU1093756325.SGD","LU1244550577.SGD","LU1244550221.USD","SG9999003800.SGD","LU0320765646.SGD","GILD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","IE00BKVL7J92.USD","LU0553294199.USD","LU1037948897.HKD","LU1718418525.SGD","LU0965509010.AUD","LU0122379950.USD","LU1674673428.USD","BK4583","SG9999015986.USD","LU1093756168.USD","BK4581","LU1057294990.SGD","SG9999001440.SGD","SG9999015945.SGD","LU1496350171.SGD","LU1839511570.USD","LU1989772840.SGD","LU2089284900.SGD","LU2237443549.SGD","LU1551013342.USD","LU2089283258.USD","LU1061106388.HKD","LU2347655156.SGD","LU0158827948.USD","LU0943347566.SGD","LU0310799852.SGD"],"gpt_icon":0},{"id":"2540953730","title":"Gilead’s Kite announces real-world safety, effectiveness of Yescarta","url":"https://stock-news.laohu8.com/highlight/detail?id=2540953730","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540953730?lang=en_us&edition=fundamental","pubTime":"2025-06-02 04:10","pubTimestamp":1748808616,"startTime":"0","endTime":"0","summary":"Kite, a Gilead (GILD) Company, announced real-world data evaluating the safety and effectiveness of Yescarta for patients with relapsed/refractory ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gileads-kite-announces-real-world-safety-effectiveness-of-yescarta-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gileads-kite-announces-real-world-safety-effectiveness-of-yescarta-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU1430594728.SGD","BK4080","LU1571399168.USD","BK4568","LU0234570918.USD","BK4532","LU0320765992.SGD","BK4583","LU1674673691.USD","LU0058720904.USD","IE00BSNM7G36.USD","BK4585","BK4578","LU0889565916.HKD","BK4139","LU1066053197.SGD","BK4231","BK4566","LU1778281490.HKD","IE00B3T34201.USD","LU1585245621.USD","BK4550","IE00BKVL7J92.USD","GILD","IE0002270589.USD","IE00B19Z3581.USD","LU2087621335.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","BK4588","LU1674673428.USD","LU1839511570.USD","LU2468319806.SGD","KRG","LU1066051498.USD","IE00B7SZLL34.SGD","LU2089984988.USD","LU0823416689.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2540312587","title":"Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540312587","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540312587?lang=en_us&edition=fundamental","pubTime":"2025-06-01 20:00","pubTimestamp":1748779234,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on June 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL1bkVxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","IE00B3T34201.USD","BK4532","LU1585245621.USD","IE0002270589.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU2089984988.USD","LU1430594728.SGD","BK4139","BK4566","BK4578","BK4550","IE00BZ1G4Q59.USD","LU0109394709.USD","LU1066053197.SGD","LU2468319806.SGD","BK4585","LU1839511570.USD","IE00B19Z3581.USD","LU0823416689.USD","LU1674673691.USD","LU1674673428.USD","BK4588","LU0289739699.SGD","LU1066051498.USD","LU1571399168.USD","BK4583","IE00BSNM7G36.USD","LU0234570918.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU0058720904.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","GILD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2540731283","title":"Gilead's CAR-T cell therapy shows promise in deadly brain cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540731283","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540731283?lang=en_us&edition=fundamental","pubTime":"2025-06-01 20:00","pubTimestamp":1748779200,"startTime":"0","endTime":"0","summary":"Gilead's CAR-T cell therapy shows promise in deadly brain cancerTherapy shrank tumors in 62% of patients in small trialResult was not lasting beyond a few months for most patients\"We're on the right t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nL2N3S304Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","LU2087621335.USD","LU2089984988.USD","BK4583","LU0234570918.USD","LU0289739699.SGD","BK4532","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4578","LU1778281490.HKD","LU1839511570.USD","BK4550","IE00B19Z3B42.SGD","LU0889565916.HKD","BK4588","LU1674673428.USD","IE0002270589.USD","LU1585245621.USD","IE00BSNM7G36.USD","GILD","LU0823416689.USD","IE00BKVL7J92.USD","LU1066053197.SGD","LU0058720904.USD","LU1571399168.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU1430594728.SGD","LU1066051498.USD","BK4139","LU2468319806.SGD","BK4585","LU0320765992.SGD","BK4568","BK4566"],"gpt_icon":0},{"id":"2539786187","title":"Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786187","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786187?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:01","pubTimestamp":1748692863,"startTime":"0","endTime":"0","summary":"Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on May 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nNDL5DpLrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4583","IE00BSNM7G36.USD","BK4578","BK4568","IE00BZ1G4Q59.USD","IE00B3T34201.USD","LU1585245621.USD","LU1778281490.HKD","BK4139","BK4588","BK4566","LU1674673428.USD","LU2468319806.SGD","LU0058720904.USD","IE0002270589.USD","BK4585","LU1066053197.SGD","LU2089984988.USD","LU0109394709.USD","GILD","LU1674673691.USD","LU1066051498.USD","LU1839511570.USD","BK4550","LU0234570918.USD","LU0889565916.HKD","IE00B19Z3581.USD","BK4532","LU0320765992.SGD","LU0289739699.SGD","IE00BKVL7J92.USD","LU0823416689.USD","LU1430594728.SGD","LU2087621335.USD","IE00B7SZLL34.SGD","LU1571399168.USD"],"gpt_icon":0},{"id":"2539786943","title":"Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539786943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539786943?lang=en_us&edition=fundamental","pubTime":"2025-05-31 20:00","pubTimestamp":1748692800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250531:nTUABMKK2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRK","SG9999014559.SGD","LU1430594728.SGD","LU2361044949.HKD","LU1291159041.SGD","SG9999002232.USD","LU2023250843.SGD","LU0861579265.USD","GILD","LU0985320562.USD","LU0106261372.USD","BK4559","BK4588","IE00BKVL7J92.USD","BK4566","IE0002141913.USD","LU0266013472.USD","LU1571399168.USD","LU0265550946.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1066051498.USD","SG9999014575.USD","IE00BBT3K403.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","SG9999013999.USD","BK4550","IE00BZ1G4Q59.USD","BK4139","LU0109394709.USD","SG9999001440.SGD","BK4583","SG9999014567.USD","LU0320765992.SGD","LU2087621335.USD","IE00BLSP4239.USD","LU1037948897.HKD","LU0289739699.SGD","BK4516","LU0234570918.USD","SG9999015358.SGD","LU0965509101.SGD","LU2361044865.SGD","LU0965508806.USD","LU1934455863.HKD","LU2023250504.SGD","LU1989771016.USD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}